Christopher Richard Anzalone sold $5.3M of ARWR
Chief Executive Officer at ARROWHEAD PHARMACEUTICALS, INC.. 300,000 shares at an average of $17.58, traded Mar 3, 2025, filed Mar 5, 2025.
Score components
- +25RoleCEO
- +25Trade size$5.3M at market
- 0Share of holdings soldSold 7.4% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -38.4%, 3m -3.5%, 6m +60.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-010672, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 3, 2025 | MOption exercise Common Stock10b5-1 | +166,667 | $7.75 | $1.3M | 3,940,469 | Mar 5, 2025 |
| Mar 4, 2025 | MOption exercise Common Stock10b5-1 | +133,333 | $7.75 | $1.0M | 4,073,802 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -166,667 | $18.03 | $3.0M | 3,907,135 | Mar 5, 2025 |
| Mar 4, 2025 | SOpen-market sale Common Stock10b5-1 | -133,333 | $17.02 | $2.3M | 3,773,802 | Mar 5, 2025 |
| Mar 3, 2025 | MOption exercise Stock Option (right to buy Common Stock)derivative10b5-1 | -166,667 | $0.00 | $0 | 185,059 | Mar 5, 2025 |
| Mar 3, 2025 | MOption exercise Stock Option (right to buy Common Stock)derivative10b5-1 | -133,333 | $0.00 | $0 | 51,726 | Mar 5, 2025 |
Related signals
Other insiders at ARROWHEAD PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 34Weak | ARROWHEAD PHARMACEUTICALS, INC. | Adeoye Y Olukotun director | $174k 2,000 shares | -6% | |
| 48Moderate | ARROWHEAD PHARMACEUTICALS, INC. | Michael S Perry director | $1.0M 11,600 shares | -9% | |
| 8Weak | ARROWHEAD PHARMACEUTICALS, INC. | Hongbo Lu director | $228k 2,970 shares | -5% | |
| 34Weak | ARROWHEAD PHARMACEUTICALS, INC. | Daniel Joseph Apel Chief Financial Officer | $934k 13,095 shares | -7% | |
| 25Weak | ARROWHEAD PHARMACEUTICALS, INC. | James C Hamilton Chief Medical Officer | $750k 10,000 shares | -4% | |
| 15Weak | ARROWHEAD PHARMACEUTICALS, INC. | James C Hamilton Chief Medical Officer | $642k 10,000 shares | -4% | |
| 43Moderate | ARROWHEAD PHARMACEUTICALS, INC. | Christopher Richard Anzalone Chief Executive Officer | $872k 13,187 shares | -0% | |
| 40Moderate | ARROWHEAD PHARMACEUTICALS, INC. | Patrick O'Brien COO | $3.1M 49,493 shares | -9% | |
| 40Moderate | ARROWHEAD PHARMACEUTICALS, INC. | James C Hamilton Chief Medical Officer | $2.5M 40,164 shares | -19% | |
| 30Weak | ARROWHEAD PHARMACEUTICALS, INC. | Christopher Richard Anzalone Chief Executive Officer | $3.6M 51,726 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.